177 related articles for article (PubMed ID: 38305755)
41. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Sam J; Hofer T; Kuettel C; Claus C; Thom J; Herter S; Georges G; Korfi K; Lechmann M; Eigenmann MJ; Marbach D; Jamois C; Lechner K; Krishnan SM; Gaillard B; Marinho J; Kronenberg S; Kunz L; Wilson S; Briner S; Gebhardt S; Varol A; Appelt B; Nicolini V; Speziale D; Bez M; Bommer E; Eckmann J; Hage C; Limani F; Jenni S; Schoenle A; Le Clech M; Vallier JP; Colombetti S; Bacac M; Gasser S; Klein C; Umaña P
Blood; 2024 May; 143(21):2152-2165. PubMed ID: 38437725
[TBL] [Abstract][Full Text] [Related]
42. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
Cremasco F; Menietti E; Speziale D; Sam J; Sammicheli S; Richard M; Varol A; Klein C; Umana P; Bacac M; Colombetti S; Perro M
PLoS One; 2021; 16(1):e0241091. PubMed ID: 33406104
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
44. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.
Bukhari A; Lee ST
Expert Rev Hematol; 2019 Nov; 12(11):909-918. PubMed ID: 31583919
[No Abstract] [Full Text] [Related]
45. Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.
Sun H; Xing H; Han L; Song Y; Jiang Z; Liu Y; Yu J
Expert Opin Biol Ther; 2024 May; 24(5):321-326. PubMed ID: 38717336
[TBL] [Abstract][Full Text] [Related]
46. Investigational drugs for the treatment of diffuse large B-cell lymphoma.
Patriarca A; Gaidano G
Expert Opin Investig Drugs; 2021 Jan; 30(1):25-38. PubMed ID: 33295827
[No Abstract] [Full Text] [Related]
47. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
Liu X; Zhao J; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
[TBL] [Abstract][Full Text] [Related]
48. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
[TBL] [Abstract][Full Text] [Related]
49. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
50. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL-6 levels following administration of the T-cell bispecific engager glofitamab.
Djebli N; Parrott N; Jaminion F; O'Jeanson A; Guerini E; Carlile D
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):396-409. PubMed ID: 38044486
[TBL] [Abstract][Full Text] [Related]
52. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
53. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
54. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
Sylvain C
Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
[TBL] [Abstract][Full Text] [Related]
55. The evolving therapy of DLBCL: Bispecific antibodies.
Hutchings M
Hematol Oncol; 2023 Jun; 41(S1):107-111. PubMed ID: 37294965
[TBL] [Abstract][Full Text] [Related]
56. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
57. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
Messori A; Rivano M; Mengato D; Chiumente M
Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
[TBL] [Abstract][Full Text] [Related]
58. Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.
Frances N; Bacac M; Bray-French K; Christen F; Hinton H; Husar E; Quackenbush E; Schäfer M; Schick E; Vyver AV; Richter WF
J Pharm Sci; 2022 Apr; 111(4):1208-1218. PubMed ID: 34953862
[TBL] [Abstract][Full Text] [Related]
59. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Davis JA; Shockley A; Glode AE
J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
[No Abstract] [Full Text] [Related]
60. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
